Compare RCUS & HIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | HIW |
|---|---|---|
| Founded | 2015 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2018 | 1995 |
| Metric | RCUS | HIW |
|---|---|---|
| Price | $20.29 | $20.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 7 |
| Target Price | ★ $29.20 | $27.71 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 9.50% |
| EPS Growth | N/A | ★ 54.26 |
| EPS | N/A | ★ 1.45 |
| Revenue | $247,000,000.00 | ★ $806,112,000.00 |
| Revenue This Year | N/A | $6.67 |
| Revenue Next Year | $70.88 | $3.61 |
| P/E Ratio | ★ N/A | $14.51 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.79 | $20.50 |
| 52 Week High | $26.40 | $32.76 |
| Indicator | RCUS | HIW |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 32.16 |
| Support Level | $18.52 | N/A |
| Resistance Level | $21.55 | $23.68 |
| Average True Range (ATR) | 1.08 | 0.56 |
| MACD | -0.27 | 0.02 |
| Stochastic Oscillator | 3.95 | 3.84 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.